A new blood test could increase the success of a popular lung cancer drug called erlotinib by allowing doctors select which patients will react positively to the drug. Currently, patients with non-small cell lung cancer receive erlotinib after chemotherapy and other drugs have failed. But erlotinib will only shrink the tumour about 10 per cent… Continue reading